We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.135 | -2.91% | 4.51 | 4.41 | 4.89 | 4.53 | 4.51 | 4.53 | 241,784 | 15:25:56 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.51 | 9.35M |
| Date | Subject | Author | Discuss |
|---|---|---|---|
| 20/7/2020 08:17 | Managed to finally get some at 105p | showmethemoneyhoney01 | |
| 20/7/2020 08:15 | from FINNCAP £3.60p tgtSynairgen released very positive results from its Phase II trial of SNG001 in hospitalised COVID-19 patients a 79% reduction in patients developing severe disease or death, with those on SNG001 more than twice as likely to recover over the treatment period than those on placebo. Both were statistically significant. Valuing the COVID-19 opportunity is nigh on impossible; however, we upgrade our target price to 360p but recognise that this could go substantially higher, based on upcoming discussions with regulators, which should clarify the route to market and the potential for buying SNG001 ahead of the winter 2020 flu season and the possibility of a second wave of COVID-19. | maccamcd | |
| 20/7/2020 08:15 | any one getting a buy quote yet a | bunz3 | |
| 20/7/2020 08:15 | Regulatory approval shouldn't take too long I assume. | trinitygooner |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
